MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

DexCom Inc

Open

SectorGezondheidszorg

72.3 1.43

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

70.9

Max

72.79

Belangrijke statistieken

By Trading Economics

Inkomsten

104M

284M

Verkoop

52M

1.2B

K/W

Sectorgemiddelde

38.633

89.037

Winstmarge

23.468

Werknemers

10,200

EBITDA

112M

421M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+20.97% upside

Dividenden

By Dow Jones

Volgende Winsten

12 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-427M

27B

Vorige openingsprijs

70.87

Vorige sluitingsprijs

72.3

Nieuwssentiment

By Acuity

50%

50%

177 / 360 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

DexCom Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 okt 2025, 18:30 UTC

Winsten

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31 okt 2025, 15:40 UTC

Winsten

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

1 jul 2025, 18:41 UTC

Acquisities, Fusies, Overnames

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

Peer Vergelijking

Prijswijziging

DexCom Inc Prognose

Koersdoel

By TipRanks

20.97% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 85.56 USD  20.97%

Hoogste 112 USD

Laagste 68 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor DexCom Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

22 ratings

18

Buy

3

Hold

1

Sell

Technische score

By Trading Central

71.66 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

177 / 360 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat